Clinical Trial Update: Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

This document reports the withdrawal of a Phase 1/2 trial evaluating BGJ398 (infigratinib), an FGFR kinase inhibitor, in combination with chemotherapy for untre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Pancreatic Cancer
• Rectal Cancer

Drugs mentioned

• BGJ398 (BGJ398)
• Combination chemotherapy

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Colon Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 1, Phase 2 | Status: WITHDRAWN